Li-Fraumeni syndrome (TP53)

Print this article

Li-Fraumeni syndrome is an inherited condition that raises the lifetime risk of a wide range of cancers, often beginning in childhood or early adulthood. It is caused by a change in a single gene, TP53. Some centers now use the broader term heritable TP53-related cancer syndrome, because carriers are increasingly identified who do not fit the pattern originally described.

This is a rare condition, affecting somewhere between 1 in 5,000 and 1 in 20,000 people. It differs from most hereditary cancer syndromes in three ways that shape everything below. The cancers are not confined to one or two organs but can arise almost anywhere. They begin far earlier than usual, including in young children. And carriers are unusually sensitive to radiation, which changes how their cancers are treated.

Against that, there is a genuinely encouraging development. A program of regular imaging, developed over the past two decades, has been shown to find these cancers at an early and treatable stage and to substantially improve survival. This is one of the few hereditary cancer syndromes where surveillance has clearly changed outcomes.

This article is written both for people diagnosed with a cancer linked to TP53 and for people who carry a gene change without having had cancer, including parents making decisions on behalf of a child.

What does the TP53 gene do?

TP53 carries the instructions for making a protein called p53, sometimes described as the guardian of the genome. It is among the most important protective genes in the body.

When a cell’s DNA is damaged, p53 acts as a checkpoint. It halts the cell from dividing, gives the repair machinery time to work, and if the damage is too severe, instructs the cell to shut itself down rather than pass the damage on. This happens constantly in every tissue.

TP53 is a tumor suppressor gene, and everyone carries two copies. A person with Li-Fraumeni syndrome is born with one working copy and one that does not work. That single copy is enough for normal life, but the checkpoint operates with less margin in every cell of the body. If the remaining copy is damaged in any one cell, that cell loses the checkpoint entirely and can begin to grow unchecked.

Because p53 protects every tissue rather than one organ, losing it produces the pattern that defines this syndrome: cancers in many different places, appearing far earlier than they otherwise would, and often more than one over a lifetime.

Cancers associated with Li-Fraumeni syndrome

Five cancers occur often enough to be described as the core cancers of this syndrome, though many others have been reported. The figures below are approximate and are discussed further in the next section.

Breast cancer in women

Breast cancer is the single most common cancer in this syndrome and the main reason lifetime risk is higher for women than for men. Cumulative risk by age 70 has been estimated at around 54% in studies of affected families, compared with about 13% in the general population. It typically occurs before menopause, frequently before age 45 and sometimes in the twenties. These cancers more often show HER2 than breast cancers in the general population.

Soft tissue sarcoma and osteosarcoma

Sarcomas are cancers arising from connective tissues such as muscle, fat, and bone. Soft tissue sarcoma has an estimated cumulative risk of around 15% by age 70, and osteosarcoma, a cancer of bone, around 5%. Both are rare in the general population, which is why their appearance at a young age often prompts genetic testing. Rhabdomyosarcoma, a soft tissue sarcoma of childhood, is particularly associated with this syndrome.

Brain tumors

Estimated cumulative risk is around 6% by age 70. A range of types occur, including gliomas at various ages and choroid plexus carcinoma, a rare tumor of infancy that is strongly associated with TP53. A child diagnosed with choroid plexus carcinoma is offered genetic testing regardless of family history.

Adrenocortical carcinoma

This cancer of the outer layer of the adrenal gland is very rare in the general population but is one of the defining cancers of this syndrome, occurring mainly in young children. Between half and four fifths of children diagnosed with it carry a germline TP53 change, so a diagnosis at any age in childhood leads directly to genetic testing, with or without a family history.

Leukemia and other cancers

Leukemia occurs in a small percentage of carriers. Beyond the core five, a wide range of other cancers has been reported at increased frequency, including cancers of the lung, colon and rectum, stomach, pancreas, ovary, and skin. What links them is not the organ but the age: they tend to appear a decade or more earlier than the same cancer would in the general population.

More than one cancer

A feature of this syndrome that sets it apart is the frequency of second and third cancers. Roughly half of carriers who develop one cancer go on to develop another. This is partly the syndrome itself and partly the effect of treatment, particularly radiation, which is why treatment decisions are made differently for carriers.

How lifetime risk is estimated and why the numbers vary

The risk figures for Li-Fraumeni syndrome are among the highest quoted for any hereditary cancer syndrome, and they are also among the most likely to be misleading for an individual carrier.

The widely cited figures, approaching 100% lifetime risk in women and around 70% to 75% in men, come from studies of families identified because they contained many cancers across several generations. Those families met strict diagnostic criteria precisely because so many members were affected. Risks calculated from them describe families like them, not every carrier.

As testing has broadened, TP53 changes have been found in people with no family history at all, in children with a single cancer, and in adults tested on a large panel for another reason. Penetrance in these less selected groups appears lower. Recent work suggests the figure for carriers identified outside classic families is closer to 80% by age 70, and lower still for some specific variants. This is an active area of research and the estimates continue to move.

Several things shift an individual’s risk:

Family history — A carrier from a family meeting classic criteria faces a higher risk than one identified incidentally.
Sex — Lifetime risk is higher for women, almost entirely because of breast cancer.
The specific variant — Changes in the region of the gene that binds DNA generally carry higher risk than changes elsewhere. One variant common in southern Brazil, known as R337H, carries a distinctly lower and different risk profile.
Whether surveillance is in place — Published risks describe the natural course of the condition. They do not describe what happens to a carrier under an effective surveillance program.

Even at the high end, these figures describe a group rather than a person. A meaningful proportion of carriers reach old age without cancer, and carriers who do develop cancer are frequently cured of it.

Who should be tested?

Genetic testing for TP53 is considered in several situations, and the criteria have widened considerably as it has become clear that many carriers have no family history.

Classic family pattern — A sarcoma before age 45, together with a close relative with any cancer before 45, and another close relative with a sarcoma at any age or another cancer before 45.
A core cancer at a young age — Sarcoma, brain tumor, adrenocortical carcinoma, or breast cancer before 46, with a close relative affected by a core cancer before 56 or with more than one cancer.
More than one cancer in the same person — Particularly when two core cancers occur and the first was before age 46.
Certain cancers regardless of family history — Adrenocortical carcinoma at any age, choroid plexus carcinoma, and anaplastic rhabdomyosarcoma in childhood all prompt testing on their own, because so many of these are caused by TP53.
Very early breast cancer — Breast cancer before age 31 is generally an indication for testing even with no other history.

A family history is not required. Between roughly 7% and 20% of TP53 changes arise new in the affected person rather than being inherited from a parent. In those families, the carrier is the first, and there is no pattern to notice.

How the test is performed

Germline testing is done on a blood or saliva sample and examines the DNA a person was born with. The analysis uses next generation sequencing together with a method that detects large deletions and duplications.

One complication is specific to TP53, and it can produce an apparently positive result in someone who does not have the syndrome. As people age, blood-forming cells in the bone marrow accumulate changes, and one clone of cells may come to make up a noticeable share of the blood. This is called clonal hematopoiesis, it is common in older adults, and TP53 is one of the genes involved. Because germline testing is usually performed on blood, a TP53 change arising this way can look like an inherited one.

Several features raise this possibility: an older person with no supporting family history, a change present in a lower proportion of cells than expected for an inherited variant, or a history of chemotherapy. When it is suspected, the laboratory confirms the result on a tissue that is not blood, usually cells cultured from a small skin sample. This distinction matters enormously, since it separates a diagnosis carrying lifelong surveillance from a finding with quite different implications.

How results are reported

Pathogenic or likely pathogenic variant — A change known, or strongly expected, to stop the gene working. This is a positive result and confirms the syndrome.
Variant of uncertain significance — A change was found but its effect is unknown. This is not a positive result. It is managed as though negative, with surveillance guided by family history, and it is never a basis for preventive surgery or for starting an intensive imaging program. Our article on variants of uncertain significance explains this result in detail.
Benign or likely benign variant — A harmless difference, usually not reported.
No variant identified — No change was found in the genes tested.

What the result means

A pathogenic or likely pathogenic variant confirms Li-Fraumeni syndrome. It means eligibility for a surveillance program, changes to how any cancer would be treated, and a 50% chance that each of the person’s children, siblings, and parents carries the same change.

A negative result means two different things:

True negative — A specific change is already known in the family and you tested negative for that exact change. You did not inherit it, your risk returns to that of the general population, and your children cannot inherit it from you. Intensive surveillance is not needed.
Uninformative negative — No change has been identified in anyone in the family. This rules out the genes tested but not an inherited cause. Families meeting classic criteria without an identified TP53 change are described as having Li-Fraumeni-like syndrome and are usually offered surveillance based on the family pattern.

Germline versus somatic TP53 changes

This distinction causes more confusion for TP53 than for any other cancer gene, for a simple reason: TP53 is the most frequently mutated gene in human cancer. Roughly half of all cancers of all types carry a TP53 change within the tumor.

A somatic change of this kind arose inside the tumor during the person’s life. It exists only in the cancer cells, cannot be passed to children, and carries no implications for relatives. It is an extremely common finding and does not indicate Li-Fraumeni syndrome.

A germline change is present in the DNA the person was born with, exists in every cell, and can be inherited. This is the syndrome, and it is rare.

Because tumor sequencing is now routine, many people are told their cancer has a TP53 mutation. In the overwhelming majority this is somatic and expected. The same applies to abnormal p53 staining on immunohistochemistry, which appears on many pathology reports and reflects a change within the tumor. Neither finding means the change is inherited. Confirming that requires a separate germline test on blood or saliva, interpreted with the clonal hematopoiesis question in mind.

Surveillance and risk reduction

Surveillance matters more in this syndrome than in almost any other, because the cancers can arise almost anywhere and no single organ can be removed to prevent them.

Whole-body imaging

The approach that changed practice is an annual whole-body MRI, combined with dedicated brain imaging and, for women, breast imaging. It was developed in Toronto and is often named for the group that established it.

The evidence behind it is unusual for a rare condition. In a prospective study, carriers who chose surveillance had markedly better survival than those who did not, because tumors were found at an earlier stage. Longer follow-up has supported that finding. MRI is used rather than CT or PET specifically because it involves no ionizing radiation.

Surveillance has costs as well. Baseline scans find something requiring follow-up in roughly a third of people, and most of those findings turn out to be harmless. Repeated scans, repeated uncertainty, and in young children the need for sedation are real burdens, and they are part of the discussion rather than a footnote.

What a typical program includes

Whole-body MRI — Annually, generally from the time the diagnosis is made, including in childhood.
Brain MRI — Annually.
Breast MRI for women — Beginning around age 20, considerably earlier than for most other hereditary breast cancer conditions.
Abdominal ultrasound in children — Every few months in early childhood, together with blood and urine tests, to detect adrenocortical carcinoma at a curable stage.
Colonoscopy — Generally every two to five years from around age 25.
Skin and clinical examination — Annually.

Programs vary between centers, and referral to a center experienced in this condition is usual, since coordinating this much imaging is not straightforward.

Risk-reducing surgery

Because cancers arise across many organs, preventive surgery has a much smaller role here than in syndromes affecting one or two sites. The exception is the breast. Risk-reducing mastectomy is discussed with women carrying a TP53 change, and the reasoning is stronger than the breast cancer risk alone would suggest, because it also avoids radiation to the chest that treatment of a breast cancer would otherwise involve. It remains an option to weigh rather than a recommendation, and breast MRI surveillance is a legitimate alternative.

Radiation

Carriers are unusually sensitive to ionizing radiation, because the cells lack the checkpoint that would normally respond to radiation-induced DNA damage. Radiation therapy given for one cancer carries a meaningfully increased risk of causing a second cancer in the treated area years later.

The practical consequences run through the whole of a carrier’s care. Where a cancer can be treated effectively without radiation, that route is generally preferred. In breast cancer this often means mastectomy rather than lumpectomy with radiation. Where radiation cannot reasonably be avoided, it is still given, and proton therapy may be considered to reduce the dose to surrounding tissue. Imaging follows the same principle, which is why MRI and ultrasound are used for surveillance rather than CT.

This does not mean radiation is forbidden. It means the balance is weighed differently, and any radiation oncologist treating a carrier will take the diagnosis into account.

Testing family members

Li-Fraumeni syndrome is inherited in an autosomal dominant pattern, meaning a single altered copy causes it. Each child, sibling, and parent of a carrier has a 50% chance of carrying the same change, and it passes through fathers exactly as through mothers.

Once a specific change is identified, relatives can be tested for that exact change through cascade testing, which is simpler and gives a clear answer.

Testing children is handled differently here than in most hereditary cancer syndromes. For conditions where surveillance begins in adulthood, testing is usually deferred until a young person can decide for themselves. In Li-Fraumeni syndrome, surveillance begins in early childhood, because adrenocortical carcinoma, choroid plexus carcinoma, and childhood sarcomas occur in the first years of life and are far more curable when found early. Testing children of carriers is therefore generally offered, and often shortly after birth. This is a difficult decision for families, and genetics services and psychologists experienced in this condition are involved in making it.

Where a TP53 change has arisen new in a person rather than being inherited, their parents and siblings are usually unaffected, though testing may still be offered because a parent can occasionally carry the change in only some of their cells.

Carriers planning a family sometimes ask whether the change can be avoided in their children. Preimplantation genetic testing, in which embryos created through IVF are tested before transfer, and prenatal testing are available in many places. A genetics service and a fertility specialist can work through these options together.

What happens next

For someone newly diagnosed with cancer, a TP53 result can change treatment immediately, particularly decisions about radiation and about how much surgery to perform. Testing is therefore usually arranged promptly rather than deferred, and it also triggers surveillance planning and family testing.

For a carrier who has not had cancer, the work is establishing a surveillance program, arranging cascade testing for relatives, and deciding about testing children. Referral to a center experienced in this syndrome is standard.

Living with this diagnosis carries a weight that goes beyond the medical arrangements. Carriers manage a lifelong schedule of scans, often alongside a family history of loss, and frequently make decisions on behalf of children. Psychological support is a routine part of care in centers that manage this condition, and patient organizations for Li-Fraumeni syndrome connect families who are navigating the same questions.

Questions to ask your doctor

Was my result confirmed as germline rather than arising from my blood cells?
Which specific variant was found, and is anything known about the risk it carries?
Given my family history, what is my estimated risk?
What does a surveillance program involve, and how often would I have scans?
How are abnormal findings on a whole-body MRI followed up?
Should I be seen at a center that specializes in this condition?
If I need treatment for a cancer, how will my diagnosis affect decisions about radiation?
If I am a woman, when should breast MRI start, and should I consider risk-reducing mastectomy?
Should my children be tested, and at what age?
What surveillance would my children need, and when would it start?
Which of my relatives should be offered testing, and can you provide a letter for them?
What reproductive options are available if I want to avoid passing this on?
Is psychological support or a patient organization available to my family?